Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Posted on by

STOCKHOLM, April 17, 2023 /PRNewswire/ — Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that a poster entitled ‘A triple combination of fostrox (MIV-818) with immune…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.